Met4Bone · Metabolites as immunomodulatory additives for biomaterials
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2020-08-01 → 2022-07-31
- EU contribution
- €152,202
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Metabolites as immunomodulatory additives for biomaterials
Biomaterials are widely used for the surgical remediation of various bone defects. However, there are still several risks associated with this treatment. The project's main goal was to develop novel biomaterials for bone regeneration with incorporated endogenous metabolites with immune regulatory properties. We applied a conceptually new approach for biomaterial development where metabolites are incorporated in biomaterials ensuring local delivery of endogenous small molecules to control cell functions. Our ambition is that fundamental knowledge and novel biomaterials generated during this project will result in new therapeutic strategies to improve the recovery of patients suffering from bone fractures.
Data: CORDIS, © European Union
Project objective
The biomaterials are crucial for the surgical remediation of bone defects caused by various diseases e.g. osteoporosis and traumatic fractures. However, there are several risks associated with this treatment; first, the surgical procedure itself carries a potential risk of inflammation and bone infection, second, the bone replacement can fail requiring revision surgery. In fact, the host immune response to implanted materials and devices is the main factor that will determine a long-term functional outcome of the biomaterial mediated treatment. Therefore, the bone biomaterial ability to modulate the local immune environment for favorable treatment outcomes has to be considered. The usage of bioactive metabolites has emerged as one of the most novel and potent approach for immune response modulation. The incorporation of metabolites with immune regulatory properties seems an especially attractive option for biomaterials as it would ensure site-specific delivery system and allow modulation of the microenvironment. The goal of this project is to develop novel biomaterials with incorporated metabolites as a potentially effective and safe strategy to modulate local immune response towards favorable outcomes of surgical bone remediation. To achieve it, the recent concept of metabolomics with the state of the art biomaterial design and research will be combined in this project. This proposal includes the transfer of knowledge to the host institution and the training of the researcher in new techniques and skills. The multidisciplinary nature of the project is strong, combining materials science, biochemistry, and molecular biology. Results have the potential to pave the way for novel biomaterials significantly improving clinical outcomes for patients suffering from bone injuries.
Original text from CORDIS.
Participants
- RIGAS TEHNISKA UNIVERSITATE · RigaCoordinatorLatvia
Links
Data: CORDIS, © European Union